PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Dis... (and make it an ideal product for use in ...)

PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Disinfectants

Date:2/19/2009

and make it an ideal product for use in healthcare settings."

Michael L. Krall, President and CEO of PURE Bioscience stated, "With more than seven thousand hospitals in Brazil - approximately the same number as in the United States -- we look forward to a productive 2009 from Lifebio. We are pleased with the commitment of Lifebio and its pursuit of the necessary regulatory registrations to sell a wide variety of SDC-based products in Brazil. In addition to general and hospital disinfectants, Lifebio expects to receive regulatory approvals for other SDC-based products in the coming months."

In March 2007, PURE granted a license to market and sell its SDC-based products in Brazil to privately held Life Biociencias S/A of Apucarana, Parana in Brazil (Lifebio), a company of Grupo Nilson Ribeiro, together in a joint venture with privately held PCI International, Inc. of Lafayette, Louisiana (PCI). In July 2008, Life Biociencias S/A received Brazilian regulatory approval for its first SDC-based general disinfectant, "Desinfetante de Uso Geral LFE 100SX."

About Life Biociencias S/A

Lifebio, established solely to develop and promote silver dihydrogen citrate as a platform technology in Brazil, is a company of Grupo Nilson Ribeiro, also headquartered in Apucarana, Parana in Brazil. Lifebio purchases concentrate from PURE for blending, packaging and distribution of non-pharmaceutical SDC-based antimicrobial products. To that end, Lifebio/PCI has constructed a facility in Apucarana, Parana dedicated to blending and packaging SDC concentrate into end use disinfectant products.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimi
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Professionals in bioscience, food-related industries turn to K-State
4. Aeon Bioscience Continues Development of Drug Eluting Stents
5. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
6. Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS

Post Your Comments:

PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Dis...(and make it an ideal product for use in ...),Health